
14/08/2025
Breaking news…
At long last, the UK medicines regulator has approved AndroFeme®, for use in postmenopausal women.
This is a big step forward for women’s health in the UK. Having had to prescribe this off-licence up until now, the MHRA has approved AndroFeme® Cream for hypoactive sexual desire dysfunction (HSDD).
Already licensed in Australia, New Zealand, and South Africa, AndroFeme® is a testosterone cream designed specifically for women. Until now, women in the UK have had to rely on unlicensed testosterone products designed specifically for men, which can be fiddly to measure and harder to use accurately.
The National Institute for Health and Care Excellence (NICE) are still to review AndroFeme® for NHS prescribing, which, if approved, could mean wider access through the NHS from 2026.
Menopause Health Matters can still prescribe AndroFeme® privately. Our specialist menopause doctors can work with you to create a personalised and tailored plan that addresses your symptoms and reflects your needs and wishes.
To book a consultation, visit our website:
https://menopausehealthmatters.co.uk/new-patients-booking/